![Wen Kong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wen Kong
Voorzitter bij Taizhou EOC Pharma Co., Ltd.
Actieve functies van Wen Kong
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Taizhou EOC Pharma Co., Ltd.
![]() Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Voorzitter | 26-12-2019 | - |
Loopbaan van Wen Kong
Opleiding van Wen Kong
Nanjing University of Aeronautics & Astronautics | Undergraduate Degree |
Statistieken
Internationaal
China | 3 |
Operationeel
Chairman | 1 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Taizhou EOC Pharma Co., Ltd.
![]() Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Health Technology |